

## Special Issue

# A Saga of Vaccine Development: Past, Present, and Future

### Message from the Guest Editors

The Special Issue “A Saga of Vaccine Development: Past, Present, And Future” aims to provide a forum for review articles that highlights vaccines in all their glory. In this Special Issue, we focus on vaccines in different times and places—the known past with its success and failures stories, the uncertain present with ongoing global pandemics, and the unknown but optimistic future that lies ahead. The topic of interest include, but are not limited to, review articles that describe interventions in vaccines:

- Exploratory phase in vaccine development;
- Preclinical phase in vaccine development;
- Clinical studies in vaccine development;
- Genetic engineering in vaccine development;
- Live attenuated virus vaccine;
- Inactivated vaccines;
- Subunit vaccines;
- Nucleic acid vaccines;
- New target for vaccination;
- Immunization;
- Vaccine platforms and delivery systems;
- Vaccines in the age current global pandemic, COVID 19.

We look forward to receiving your contributions.

---

### Guest Editors

Dr. Suman Chowdhury

Department of Pharmacology, Physiology, Neuroscience, NJMS, Rutgers University, Newark, NJ 07103, USA

Dr. Ranjeet Kumar

Department of Pharmacology, Physiology, Neuroscience, NJMS, Rutgers University, Newark, NJ 07103, USA

---

### Deadline for manuscript submissions

closed (30 September 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/155319](https://mdpi.com/si/155319)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).